With no upfront payment or milestones on the line, Nkarta and CRISPR join forces on CAR-NK search
Most deals in biotech come with hefty upfront payments attached, and the promise of big biobucks if a program works out. Not this one.
Nkarta has struck what CEO Paul Hastings calls a “real collaboration” with CRISPR Therapeutics to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The duo will split all R&D costs — and any worldwide profits — 50/50, Hastings said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.